PK11195, a peripheral benzodiazepine receptor ligand, potentiates cytotoxic action on cholangiocarcinoma cell lines
Journal
HPB
Date Issued
2011
DOI
10.1111/j.1477-2574.2011.00308.x
Abstract
Cholangiocarcinoma (CC) is an uncommon disease with a
dismal prognosis. Patients with surgically unresectable disease benefi t little from conventional anticancer therapies
such as chemotherapy and radiotherapy. 1-(2-chlorophenylN-methylpropyl)-3-isoquinolinecarboxamide (PK11195) is a
benzodiazepine receptor ligand which antagonizes Bcl-2 and
Bcl-XL function thus preventing the inhibition of apoptosis.
Our aim was to determine the effect of adding PK11195 in
vitro to commercially available chemotherapy agents on
cultured CC cell lines.
dismal prognosis. Patients with surgically unresectable disease benefi t little from conventional anticancer therapies
such as chemotherapy and radiotherapy. 1-(2-chlorophenylN-methylpropyl)-3-isoquinolinecarboxamide (PK11195) is a
benzodiazepine receptor ligand which antagonizes Bcl-2 and
Bcl-XL function thus preventing the inhibition of apoptosis.
Our aim was to determine the effect of adding PK11195 in
vitro to commercially available chemotherapy agents on
cultured CC cell lines.
Subjects